News round-up for 15-19 May by DDW Digital Content Editor Diana Spencer.
It’s Clinical Trials Day tomorrow and this week we have reported on the launch of a number of new Phase I trials. In-human studies have been initiated to test treatments for Parkinson’s disease, radioactive contamination, Dravet Syndrome, influenza and inflammatory diseases.
The top stories:
New trial will investigate LRRK2 inhibitors for Parkinson’s
A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland.
Phase I trial launches into oral drug for radioactive contamination
A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun.
Bloom Science completes enrolment in Dravet Syndrome trial
Bloom Science has completed enrolment in all four cohorts of healthy adult participants as part of its Phase I clinical trial.
mRNA universal influenza vaccine enters clinical trials
A clinical trial of an experimental universal influenza vaccine has begun enrolling volunteers at Duke University in Durham, North Carolina.
First-in-human Phase I study of KMO inhibitor launches in UK
Scotland-based Kynos Therapeutics has launched a first-in-human Phase I trial of its kynurenine 3-monooxygenase (KMO) inhibitor KNS366.
